

General Battery Corporation (the fourth signatory to the Decree and a major generator of waste disposed of at the Site) providing access to the Site, the Shaners' cooperation during the cleanup, permanent use restrictions on the Site and preservation of a portion of the Site as a permanent wilderness area; and (3) to waive any claims for Takings under the Fifth Amendment of the United States Constitution and claims for statutory relocation benefits. By signing the Decree, General Battery Corporation ("GBC") has agreed: (1) To reimburse the Hazardous Substances Superfund in the amount of \$3,000,000, (2) to pay \$24,000 in past natural resource costs to the federal natural resources trustees (the National Oceanographic and Atmospheric Administration ("NOAA") and the Department of Interior ("DOI")); (3) to pay certain of EPA's future response costs; (4) to pay up to \$10,000 of DOI's future costs; (5) to perform those activities required by the Record of Decision ("ROD") for Operable Unit Two of the final Site remedy (excavating lead contaminated soil above 1000 parts per million, transport of the contaminated soil to GBC's off-Site innovative thermal treatment facility, and treatment of the deep and shallow groundwater) and complete those activities required by the ROD for Operable Unit One of the final Site remedy (constructing a fence around the property); and (6) to perform extensive work to protect natural resources at the Site as required by DOI and NOAA.

The Department of Justice will receive, for a period of thirty (30) days from the date of this publication, comments relating to the proposed consent decree. Comments should be addressed to the Assistant Attorney General for the Environment and Natural Resources Division, Department of Justice, Washington, D.C. 20530, and should refer to *United States v. Terry Shaner, et al.*, DOJ Ref. # 90-11-3-76.

The proposed consent decree may be examined at the Office of the United States Attorney, Eastern District of Pennsylvania, 615 Chestnut Street, Suite 1250, Philadelphia, Pennsylvania, 19106-4476; the Region III Office of the Environmental Protection Agency, 841 Chestnut Building, Philadelphia, Pennsylvania, 19107; and at the Consent Decree Library, 1120 G Street NW., 4th Floor, Washington, DC 20005, (202) 624-0892. A copy of the proposed consent decree may be obtained in person or by mail from the Consent Decree Library, 1120 G Street NW., 4th Floor, Washington, DC 20005. In requesting a copy of the body of the proposed decree, please refer to the

referenced case and enclose a check in the amount of \$41.25 (25 cents per page reproduction costs), for each copy. The check should be made payable to the Consent Decree Library. If copies of the proposed consent decree attachments are requested, enclose \$167.25 (an additional \$126.00 is required for the attachments).

Bruce S. Gelber,

Acting Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 95-18429 Filed 7-26-95; 8:45 am]

BILLING CODE 4410-01-M

Drug Enforcement Administration

[DEA #134P]

Controlled Substances: Proposed Aggregate Production Quotas for 1996

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of proposed aggregate production quotas for 1996.

SUMMARY: This notice proposes initial 1996 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act.

DATES: Comments or objections should be received on or before August 28, 1995.

ADDRESSES: Send comments or objections to the Deputy Administrator, Drug Enforcement Administration, Washington, DC 20537, Attn: DEA Federal Register Representative (CCR).

FOR FURTHER INFORMATION CONTACT: Howard McClain, Jr., Chief, Drug & Chemical Evaluation Section, Drug Enforcement Administration, Washington, D.C. 20537, Telephone: (202) 307-7183.

SUPPLEMENTARY INFORMATION: Section 306 of the Controlled Substances Act (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations.

The Administrator, in turn, has re-delegated this function to the Deputy Administrator pursuant to § 0.104 of Title 28 of the Code of Federal Regulations.

The quotas are to provide adequate supplies of each substance for: (1) The estimated medical, scientific, research, and industrial needs of the United States; (2) lawful export requirements; and (3) the establishment and maintenance of reserve stocks.

In determining the below listed proposed 1996 aggregate production quotas, the Deputy Administrator considered the following factors: (1) Total actual 1994 and estimated 1995 and 1996 net disposals of each substance by all manufacturers; (2) estimates of 1995 year-end inventories of each substance and of any substance manufactured from it and trends in accumulation of such inventories; and (3) projected demand as indicated by procurement quota applications filed pursuant to § 1303.12 of title 21 of the Code of Federal Regulations.

Pursuant to § 1303.23(c) of title 21 of the Code of Federal Regulations, the Deputy Administrator of the DEA will, in early 1996, adjust aggregate production quotas and individual manufacturing quotas allocated for the year based upon 1995 year-end inventory and actual 1995 disposition data supplied by quota recipients for each basic class of Schedule I or II controlled substance.

Therefore, under the authority vested in the Attorney General by section 306 of the Controlled Substances Act of 1970 (21 U.S.C. 826), delegated to the Administrator of the DEA by § 0.100 of title 28 of the Code of Federal Regulations, and re-delegated to the Deputy Administrator pursuant to § 0.104 of title 28 of the Code of Federal Regulations, the Deputy Administrator hereby proposes that the aggregate production quotas for 1996 for the following controlled substances, expressed in grams of anhydrous acid or base, be established as follows:

Basic class	Proposed 1996 quotas
Schedule I:	
Acetylmethadol	7
Alphacetylmethadol	7
Aminorex	7
Cathinone	9
Difenoxin	14,000
Dihydromorphine	7
2,5-Dimethoxyamphetamine .	10,650,000
Dimethylamphetamine	7
Ethylamine Analog of	
Phencyclidine	5
N-Ethylamphetamine	7
Lysergic acid diethylamide	58
Mescaline	7
Methaqualone	17
Methcathinone	9
4-Methoxyamphetamine	17
4-Methylaminorex	2
3,4-	
Methylenedioxyamphetami-	
ne	17
3,4-Methylenedioxy-N-	
ethylamphetamine	27
3,4-	
Methylenedioxymethamph-	
etamine	42
3-Methylfentanyl	14

Basic class	Proposed 1996 quotas
Normethadone	7
Normorphine	7
Psilocybin	2
Psilocyn	2
Tetrahydrocannabinols	55,100
Schedule II:	
Alfentanil	8,500
Amobarbital	15
Amphetamine	1,300,100
Cocaine	550,040
Codeine (for sale)	58,395,000
Codeine (for conversion)	16,632,000
Desoxyephedrine, 1,000,000 grams of levodesoxyephedrine for use in a noncontrolled, nonprescription product and 44 kg for methamphetamine.	1,044,000
Dextropropoxyphene	118,066,000
Dihydrocodeine	60,000
Diphenoxylate	1,063,000
Ecgonine (for conversion)	650,100
Ethylmorphine	12
Fentanyl	120,100
Hydrocodone (for sale)	8,880,000
Hydrocodone (for conversion)	2,800,000
Hydromorphone	448,000
Isomethadone	12
Levo-alpha-acetylmethadol ...	200,000
Levorphanol	14,300
Meperidine	10,822,000
Methadone	4,551,000
Methadone (for conversion) ..	364,000
Methadone Intermediate (for conversion)	5,534,000
Methamphetamine (for conversion)	723,000
Methylphenidate	10,291,000
Morphine (for sale)	12,450,000
Morphine (for conversion)	76,735,000
Noroxymorphone (for sale) ...	2,000
Noroxymorphone (for conversion)	2,406,000
Opium	1,226,000
Oxycodone (for sale)	5,571,000
Oxycodone (for conversion) ..	37,300
Oxymorphone	11,200
Pentobarbital	15,100,000
Phencyclidine	40
Phenylacetone (for conversion)	5,280,000
1-Phenylcyclohexylamine	10
1-Piperidinocyclohexanecarbonitrile	12
Secobarbital	400,000
Sufentanil	1,000
Thebaine	9,217,000

The Deputy Administrator further proposes that aggregate production quotas for all other Schedules I and II controlled substances included in §§ 1308.11 and 1308.12 of title 21 of the Code of Federal Regulations be established at zero.

All interested persons are invited to submit their comments and objections in writing regarding this proposal. A person may object to or comment on the proposal relating to any of the above-

mentioned substances without filing comments or objections regarding the others. If a person believes that one or more of these issues warrant a hearing, the individual should so state and summarize the reasons for this belief.

In the event that comments or objections to this proposal raise one or more issues which the Deputy Administrator finds warrant a hearing, the Deputy Administrator shall order a public hearing by notice in the **Federal Register**, summarizing the issues to be heard and setting the time for the hearing.

The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. This action has been analyzed in accordance with the principles and criteria contained in Executive Order 12612, and it has been determined that this matter does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment.

The Deputy Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601, et seq. The establishment of annual aggregate production quotas for Schedules I and II controlled substances is mandated by law and by international treaty obligations. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Deputy Administrator has determined that this action does not require a regulatory flexibility analysis.

Dated: July 19, 1995.
Stephen H. Greene,
Deputy Administrator.
 [FR Doc. 95-18407 Filed 7-26-95; 8:45 am]
BILLING CODE 4410-09-M

Manufacturer of Controlled Substances; Registration

By Notice dated May 30, 1995, and published in the **Federal Register** on June 8, 1995 (60 FR 30318), Research Triangle Institute, Kenneth H. Davis, Jr., Hermann Building, East Institute Drive, P.O. Box 12194, Research Triangle Park, North Carolina 27709, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Marihuana (7360)	I
Cocaine (9041)	II

No comments or objections have been received. Therefore, pursuant to section 303 of the Comprehensive Drug Abuse Prevention and Control Act of 1970 and Title 21, Code of Federal Regulations, § 1301.54(e), the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

Dated: July 19, 1995.
Gene R. Haislip,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
 [FR Doc. 95-18408 Filed 7-26-95; 8:45 am]
BILLING CODE 4410-09-M

Importer of Controlled Substances; Registration

By Notice dated May 30, 1995, and published in the Federal Register on June 8, 1995, (60 FR 30319), Research Triangle Institute, Kenneth H. Davis, Jr., Hermann Building, East Institute Drive, P.O. Box 12194, Research Triangle Park, North Carolina 27709, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed below:

Drug	Schedule
Marihuana (7360)	I
Cocaine (9041)	II

No comments or objections have been received. Therefore, pursuant to section 1008(a) of the Controlled Substances Import and Export Act and in accordance with title 21, Code of Federal Regulations, § 1311.42, the above firm is granted registration as an importer of the basic classes of controlled substances listed above.

Dated: July 19, 1995.
Gene R. Haislip,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
 [FR Doc. 95-18409 Filed 7-26-95; 8:45 am]
BILLING CODE 4410-09-M